536565
TRIMURTHI
Start SIP
Invest Now
Start SIP in TRIMURTHI
Performance
- Low
- ₹62
- High
- ₹63
- 52 Week Low
- ₹25
- 52 Week High
- ₹70
- Open Price₹63
- Previous Close₹61
- Volume1,251
- 50 DMA₹58.45
- 100 DMA₹54.24
- 200 DMA₹45.62
Investment Returns
- Over 1 Month + 12.46%
- Over 3 Month + 12.24%
- Over 6 Month + 52.2%
- Over 1 Year + 148.09%
Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!
Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 60.6
- PEG Ratio
- 0.1
- Market Cap Cr
- 111
- P/B Ratio
- 3.9
- Average True Range
- 3.69
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- 1.01
- RSI
- 54.44
- MFI
- 63.81
Novelix Pharmaceuticals Financials
Novelix Pharmaceuticals Technicals
EMA & SMA
Current Price
₹62.89
+
1.6
(2.61%)
- Bearish Moving Average 0
- Bullish Moving Average 16
- 20 Day
- ₹60.41
- 50 Day
- ₹58.45
- 100 Day
- ₹54.24
- 200 Day
- ₹45.62
Resistance and Support
60.93
- R3 68.46
- R2 65.83
- R1 63.56
- S1 58.66
- S2 56.03
- S3 53.76
Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-02-12 | Quarterly Results | |
| 2025-11-13 | Quarterly Results | |
| 2025-08-14 | Quarterly Results & A.G.M. | |
| 2025-06-24 | Others | Inter alia, to consider and approve 1. The conversion of Warrants into Equity Shares of the Company. |
| 2025-05-27 | Audited Results |
Novelix Pharmaceuticals F&O
About Novelix Pharmaceuticals
- NSE Symbol
- TRIMURTHI
- BSE Symbol
- 536565
- ISIN
- INE314I01036
Similar Stocks to Novelix Pharmaceuticals
Novelix Pharmaceuticals FAQs
Novelix Pharmaceuticals share price is ₹62 As on 13 February, 2026 | 13:29
The Market Cap of Novelix Pharmaceuticals is ₹110.8 Cr As on 13 February, 2026 | 13:29
The P/E ratio of Novelix Pharmaceuticals is 60.6 As on 13 February, 2026 | 13:29
The PB ratio of Novelix Pharmaceuticals is 3.9 As on 13 February, 2026 | 13:29
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.